BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 12114432)

  • 1. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Lord RV; Brabender J; Gandara D; Alberola V; Camps C; Domine M; Cardenal F; Sánchez JM; Gumerlock PH; Tarón M; Sánchez JJ; Danenberg KD; Danenberg PV; Rosell R
    Clin Cancer Res; 2002 Jul; 8(7):2286-91. PubMed ID: 12114432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
    Jiang CP; Wu BH; Chen SP; Fu MY; Yang M; Liu F; Wang BQ
    Tumour Biol; 2013 Feb; 34(1):415-20. PubMed ID: 23108892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
    Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
    Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
    Ren S; Zhou S; Zhang L; Xu J; Lv M; Zhang J; Zhou C; Zhang J
    Cancer Invest; 2010 Dec; 28(10):1078-83. PubMed ID: 20504223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
    Sad LM; Younis SG; Elity MM
    Med Oncol; 2014 Jul; 31(7):58. PubMed ID: 24935625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
    Comella P; Frasci G; Panza N; Manzione L; Lorusso V; Di Rienzo G; Cioffi R; De Cataldis G; Maiorino L; Bilancia D; Nicolella G; Natale M; Carpagnano F; Pacilio C; De Lena M; Bianco A; Comella G
    J Clin Oncol; 1999 May; 17(5):1526-34. PubMed ID: 10334540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
    Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
    Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Tibaldi C; Giovannetti E; Vasile E; Mey V; Laan AC; Nannizzi S; Di Marsico R; Antonuzzo A; Orlandini C; Ricciardi S; Del Tacca M; Peters GJ; Falcone A; Danesi R
    Clin Cancer Res; 2008 Mar; 14(6):1797-803. PubMed ID: 18347182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    Booton R; Ward T; Ashcroft L; Morris J; Heighway J; Thatcher N
    J Thorac Oncol; 2007 Oct; 2(10):902-6. PubMed ID: 17909351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.
    Han JY; Lee GK; Lim KY; Lee YJ; Nam BH; Lee JS
    Cancer Res Treat; 2017 Jul; 49(3):678-687. PubMed ID: 27737534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
    Rosell R; Danenberg KD; Alberola V; Bepler G; Sanchez JJ; Camps C; Provencio M; Isla D; Taron M; Diz P; Artal A;
    Clin Cancer Res; 2004 Feb; 10(4):1318-25. PubMed ID: 14977831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic testing for chemotherapy in non-small cell lung cancer.
    Rosell R; Taron M; Alberola V; Massuti B; Felip E
    Lung Cancer; 2003 Aug; 41 Suppl 1():S97-102. PubMed ID: 12867068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
    Villalobos M; Czapiewski P; Reinmuth N; Fischer JR; Andreas S; Kortsik C; Serke M; Wolf M; Neuser P; Reuss A; Schnabel PA; Thomas M
    Med Oncol; 2018 Jun; 35(7):106. PubMed ID: 29905882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
    Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
    Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of genetic markers on survival in non-small cell lung cancer.
    Rosell R; Taron M; Camps C; López-Vivanco G
    Drugs Today (Barc); 2003 Oct; 39(10):775-86. PubMed ID: 14668933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer.
    Wu JJ; Jiao SC
    Asian Pac J Trop Med; 2013 Nov; 6(11):908-11. PubMed ID: 24083589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
    Qiu ZQ; Zhao K
    Asian Pac J Cancer Prev; 2014; 15(17):7303-7. PubMed ID: 25227833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.